Allogeneic Stem Cell Transplantation: Clinical Research and by Frederick R. Appelbaum MD (auth.), Mary J. Laughlin MD,

By Frederick R. Appelbaum MD (auth.), Mary J. Laughlin MD, Hillard M. Lazarus MD (eds.)

Show description

Read or Download Allogeneic Stem Cell Transplantation: Clinical Research and Practice PDF

Similar clinical books

Urological Tests in Clinical Practice

This concise pocket consultant to urological investigative approaches stories the indicators and pitfalls of exams sooner than they're asked and indicates which checks may be played in person urological stipulations. half I describes the rules, technique, benefits and drawbacks of every of the investigations and covers all urological investigations/tests.

Clinical Applications of Immunotoxins

1 2 D. FITZGERALDI, I. PASTAN , and J. ROBERTUS creation . . . . . . . . . . . . . I 2 Toxin Structure-Function homes 2 2. 1 capabilities. . . . . . . . . . . . . . . . . . . . . . . . 2 2. 2 Binding. . . . . . . . . . . . . . . . . . . . . . . . . three three Intracellular Processing - Cleavage and aid .

Additional resources for Allogeneic Stem Cell Transplantation: Clinical Research and Practice

Sample text

Conversely, patients who are BCR/ABL+ following transplantation seem to be at high risk for subsequent relapse. 025) (48). The prognostic significance of the PCR assay remained after controlling for other variables that could influence relapse risk. The risk of relapse was greater for patients with a p190 fusion transcript than for those with p210 BCR/ABL. The median time from detection of a positive PCR result to relapse was 94 d. Additional insights into the kinetics of disappearance of BCR/ABL will be obtained from current studies using real-time PCR techniques to quantify transcript number reproducibly (49,50).

EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology. Basic Principles and Practice, 3rd ed. Churchill Livingstone, New York, 2000, pp. 1106–1129. 25. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199. 26. Pedersen-Bjergaard J. Radiotherapy-and-chemotherapy-induced myelodysplasia and acute myeloid leukemia: a review. Leuk Res 1992;16:61–65. 27. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin’s disease.

Blood 1996;87:51–58. 55. O’Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995;13:2973–2979. 56. De Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group. Br J Haematol 1990;74:151–155. 57. Runde V, de Witte T, Arnold R, et al.

Download PDF sample

Rated 4.53 of 5 – based on 9 votes